Table 2 The relationship between the expression of PLK1 and p-PLK1 and clinical characteristics in 40 cases of NK/T-cell lymphoma [cases (%)]
From: The expression and clinical significance of PLK1/p-PLK1 protein in NK/T cell Lymphoma
Clinical features | Cases | Low expression of PLK1 | High expression of PLK1 | P value | Low expression of p-PLK1 | High expression of p-PLK1 | P value |
|---|---|---|---|---|---|---|---|
Gender | 0.053 | 0.145 | |||||
Male | 27 | 11(40.7) | 16(59.3) | 11(40.7) | 16(59.3) | ||
Female | 13 | 9(69.2) | 4(30.8) | 9(69.2) | 4(30.8) | ||
Age(years) | 0.204 | 0.204 | |||||
≤ 51 | 20 | 12(60.0) | 8(40.0) | 12(60.0) | 8(40.0) | ||
> 51 | 20 | 8(40.0) | 12(60.0) | 8(40.0) | 12(60.0) | ||
Ann Arbor stage | 0.677 | 0.096 | |||||
I/II stage | 28 | 14(50.0) | 14(50.0) | 17(60.7) | 11(39.3) | ||
III/IV stage | 12 | 6(50.0) | 6(50.0) | 3(25.0) | 9(75.0) | ||
PINK-E score | 0.781 | 0.781 | |||||
0–1 score | 28 | 13(46.4) | 15(53.6) | 14(50.0) | 14(50.0) | ||
2–3 score | 12 | 7(58.3) | 5(41.7) | 6(50.0) | 6(50.0) | ||
B symptoms | 0.775 | 0.726 | |||||
yes | 19 | 9(47.4) | 10(52.6) | 9(47.4) | 10(52.6) | ||
no | 21 | 11(52.4) | 10(47.6) | 11(52.4) | 10(47.6) | ||
LDH(U/L) | 0.97 | 0.769 | |||||
< 245 | 23 | 12(52.2) | 11(47.8) | 12(52.2) | 11(47.8) | ||
≥ 245 | 14 | 7(50.0) | 7(50.0) | 7(50.0) | 7(50.0) | ||
β2 microglobulin(mg/L) | 0.248 | 0.452 | |||||
< 3 | 27 | 14(51.9) | 13(48.1) | 15(55.6) | 12(44.4) | ||
≥ 3 | 8 | 3(37.5) | 5(62.5) | 3(37.5) | 5(62.5) | ||
Blood EBV-DNA | 0.274 | 0.346 | |||||
Normal | 21 | 12(57.1) | 9(42.9) | 13(62.0) | 8(38.0) | ||
Increase | 5 | 2(40.0) | 3(60.0) | 3(60.0) | 2(40.0) | ||
Bone marrow invasion | 0.455 | 0.576 | |||||
Yes | 1 | 0(00.0) | 1(100.0) | 0(00.0) | 1(100.0) | ||
No | 32 | 16(50.0) | 16(50.0) | 16(50.0) | 16(50.0) | ||
Lymph node metastasis | 0.591 | 0.635 | |||||
Yes | 3 | 2(66.7) | 1(33.3) | 1(33.3) | 2(66.7) | ||
No | 31 | 15(48.4) | 16(51.6) | 15(48.4) | 16(51.6) |